Production (Stage)
Oramed Pharmaceuticals Inc.
ORMP
$2.22
$0.073.26%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 25.00% | 48.07% | -312.97% | 499.74% | -88.48% |
| Total Depreciation and Amortization | -3.23% | -40.38% | -3.70% | -3.57% | 5.66% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -31.16% | -24.04% | 215.63% | -283.78% | 82.99% |
| Change in Net Operating Assets | -10,593.33% | -99.08% | -25.34% | 448.56% | -38.50% |
| Cash from Operations | -84.14% | 73.09% | -442.05% | 240.65% | -4.09% |
| Capital Expenditure | 72.73% | -120.00% | -- | 100.00% | 33.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 53.02% | 145.06% | -136.19% | 215.52% | 0.00% |
| Cash from Investing | 53.11% | 145.02% | -136.19% | 215.54% | 0.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | -60.79% | 24.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | 7.44% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 7.44% | 95.77% | -60.79% | 24.00% |
| Foreign Exchange rate Adjustments | 50.00% | -166.67% | 175.00% | -300.00% | -112.50% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 63.17% | 128.88% | -164.45% | 595.06% | 165.43% |